Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent attacks of severe abdominal pain, vomiting, and swelling of the hands, feet, arms, legs, face and airway. The disorder is caused by a shortage of C1 inhibitor protein, which regulates certain blood proteins called kinins and prevents swelling. Until recent advances, treatment options were limited to drugs like androgens and antifibrinolytics which help prevent attacks but do not treat them. However, with advancements in recombinant human C1 inhibitor therapies, targeted prophylaxis and on-demand treatment have become possible for HAE patients.

The Global Hereditary Angioedema Market is estimated to be valued at US$ 3158.05 Mn in 2024 and is expected to exhibit a CAGR of 9.1% over the forecast period 2024 To 2031.

Key Takeaways

Key players operating in the Hereditary Angioedema market are CSL Behring, Takeda Pharmaceutical Company Limited., Pharming, BIOCRYST PHARMACEUTICALS, INC., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, CENTOGENE N.V., and Sanofi. The market offers huge opportunities for targeted drug development in the areas of prophylaxis and on-demand treatment. Advancements in gene therapy and RNA interference approaches also hold promise for establishing an effective cure for HAE in the long run.

Market Drivers

The Global Hereditary Angioedema Market Growth is driven by growing disease awareness among patients and physicians. Rising access to modern diagnoses and frequent new drug approvals are also supporting the market growth. The launch of novel recombinant therapies as well as ongoing clinical trials exploring other mechanisms of action will likely substantiate the treatment landscape further. Additionally, the lack of effective prophylactic drugs and high unmet needs indicate scope for premium priced novel therapeutics, ensuring lucrative returns on investment for market stakeholders.

Current challenges in Hereditary Angioedema industry:
The Hereditary Angioedema industry is facing major challenges in research and development of novel treatment options. Development of new drugs is a lengthy and expensive process which requires large investments. Currently available treatment options like C1 esterase inhibitor medications provide temporary relief and are very costly. Lack of disease awareness among general population and even many healthcare professionals makes management and treatment more difficult. Receiving timely diagnosis and treatment remains a challenge for many patients.

Get more insights on Hereditary Angioedema Market

Explore more Articles related Dental Implants Market

For Deeper Insights, Find the Report in the Language that You want

• French
• German
• Italian
• Russian
• Japanese
• Chinese
• Korean
• Portuguese

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.

(https://www.linkedin.com/in/ravina-pandya-1a3984191)